Between June 1988 and May 1996, 428 patients underwent allogeneic BMT (288 related donor (RD) and 140 unrelated donor (UD)) at the Vancouver General Hospital. Eight patients (UD six and RD two) developed a post-transplant lymphoproliferative disorder (PTLD). Median age at BMT was 38 years (range 22-51). Five of the six UD allografts were T cell depleted. Cyclosporine ± methotrexate was used for GVHD prophylaxis. All eight patients developed GVHD; in six this was refractory to treatment with corticosteroids. Post-transplant lymphoproliferative disorders (PTLD) have been well documented after solid organ transplantation, with an incidence that varies from 2% in renal transplant recipients to 30% in those undergoing intestinal and multiorgan transplants.
Post-transplant lymphoproliferative disorders (PTLD) have been well documented after solid organ transplantation, with an incidence that varies from 2% in renal transplant recipients to 30% in those undergoing intestinal and multiorgan transplants. 1 After BMT, the incidence of PTLD is reported to be Ͻ1%, although the risk of this complication increases significantly with HLA disparity, ex vivo T cell depletion of the allograft, severe GVHD and in vivo anti-T cell therapy. [2] [3] [4] [5] For patients with these risk factors, the incidence has been reported to be as high as 15-25%. [2] [3] [4] In this retrospective review of our experience with PTLD in patients undergoing allogeneic BMT at the Vancouver General Hospital, a study period of 8 years (June 1988 to May 1996) was selected so that all recipients of unrelated donor BMT would be included. The report here is written against the background of a consensus meeting held recently in Chicago (International Consensus Development Meeting on EBV-induced PTLD, May 1997).
Patients and methods

Study population
From June 1988 to May 1996, 428 patients underwent first allogeneic BMT with related donor (RD, 288) or unrelated donor (UD, 140) marrow grafts. Eighteen of the RD and 35 of the UD allografts were mismatched. T cell depletion of the allograft was performed in five of the RD and 39 of the UD transplants. Details of this study population are outlined in Table 1 .
Patients with PTLD
Eight patients developed PTLD following BMT; UD six and RD two. All eight patient/donor pairs were matched at the HLA A, B and DR loci. DR typing was by molecular methods in six patients and serological methods in two patients. The characteristics of these eight patients are shown in Table 2 . Median age at BMT was 38 years (range . Hematological diagnosis was CML in three, AML in two, multiple myeloma in two and lymphoblastic lymphoma in one. In five of the six UD allografts, marrow was T cell depleted by immunomagnetic separation using an anti-CD3 monoclonal antibody. 6 One patient (UPN 954) Immunomagnetic separation using anti-CD3 monoclonal antibody (n = 37), elutriation (n = 5) or Ceprate column (n = 2).
c Xomazyme, BT 563. RD = related donor; UD = unrelated donor; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; MM = multiple myeloma; SAA = severe aplastic anemia; TBI = total body irradiation; ATG = antithymocyte globulin; Bu = busulfan; TCD = T cell depletion; GVHD = graft-versus-host disease; CsA = cyclosporin A; MTX = methotrexate; MP = methylprednisolone; Xomazyme = anti-CD5-ricin A chain immunotoxin; BT 563 = anti-interleukin-2 receptor monoclonal antibody.
developed secondary graft failure, underwent second BMT with a T replete graft from the same unrelated donor and developed PTLD after the second BMT. Conditioning regimens consisted of cyclophosphamide (50 mg/kg/day × 3), thiotepa (150 mg/m 2 ), equine antithymocyte globulin ((ATG) ATGAM; Upjohn, Kalamazoo, MI, USA, 30 mg/kg/day × 3), methylprednisolone (5 mg/kg/day × 4) and 1200 cGy fractionated TBI in the five patients who underwent T cell-depleted UD BMT. For the one patient who developed graft failure, the preparative regimen for the second BMT was cyclophosphamide (50 mg/kg/day × 4), rabbit ATG (Thymoglobuline; Sangstat Medical Corporation, Menlo Park, CA, USA, 5 mg/kg/day × 3) and methylprednisolone (5 mg/kg/ day × 4). The patient who underwent T replete UD BMT received a conditioning regimen of cyclophosphamide (2 g/m 2 /day × 3), etoposide (1.8 g/m 2 ) and 1000 cGy TBI.
One of the two patients undergoing RD BMT received busulfan (4 mg/kg/day × 4) and cyclophosphamide (60 mg/kg/day × 2) and the other received busulfan (3 mg/kg/day × 4), cyclophosphamide (90 mg/kg) and melphalan (100 mg/m 2 ). GVHD prophylaxis was CsA and T cell depletion in five cases and CsA with short-course methotrexate (MTX) 7 in four (including UPN 954 for second BMT). Acute GVHD, by standard grading criteria, 8, 9 occurred in all eight patients; grade II (four), grade III (two) and grade IV (two). All patients were treated with corticosteroids (methylprednisolone 2-5 mg/kg/day for 5 days with tapering if effective) as first-line therapy. Six patients had corticosteroid refractory disease requiring second-line therapy; rabbit ATG (2.5 mg/kg/day × 4) was used in five and anti-CD5-ricin A chain immunotoxin (Xomazyme; XOMA Corporation, Berkeley, CA, USA, 0.1 mg/kg/day × 14) was used in one. All patients responded to second-line therapy. Three had subsequent exacerbations of GVHD requiring further immunosuppressive therapy: one required treatment with a second course of ATG, FK 506, thalidomide and psoralen ultraviolet (PUVA); one required addition of thalidomide and one was treated with FK 506.
EBV serology pre-BMT was available in five patient/donor pairs and was seropositive in all with the exception of a single donor. Three patient/donor pairs were CMV seronegative. All others were either patient and/or donor CMV seropositive. HSV serology was positive in five and negative in three patients.
Acyclovir was used for HSV prophylaxis in all seropositive patients from day 1 post BMT until engraftment. Ganciclovir was given for CMV prophylaxis in all seropositive patients or donors beginning from engraftment until day 100 or longer if patients remained on prednisone Ͼ1 mg/kg/day. One patient (UPN 954) was receiving acyclovir and foscarnet for recurrent oral HSV at the development of PTLD. Five patients had received acyclovir earlier in the post-BMT course. Four patients were on ganciclovir at the development of PTLD.
Pathology
Biopsy specimens were obtained during life in three patients (liver two, tonsil one) and at post mortem in the remaining five patients. Diagnoses were established by clinicopathological correlation using routine histology, immunohistochemistry, flow cytometry and molecular genetics when fresh tissue was available. Detection of EBV was performed by paraffin section immunohistochemistry using latent membrane protein (LMP) immunostaining in eight cases and by PCR in five cases. The presence of clonality was determined by light chain restriction using immunohistochemistry (five cases) and by flow cytometry and/or PCR to show rearrangement of the immunoglobulin heavy chain gene using a single set of consensus primers to the framework III and joining region gene segments (four cases). 10 
Statistical analysis
Univariate and multivariate analyses were performed using Cox's proportional hazards model. 11 The following vari- 
Results
Clinical presentation
Symptoms/signs related to PTLD occurred at median day 71.5 (range 34-282) post BMT. This does not include two patients, UPN 258 and 1006, who were asymptomatic and in whom PTLD was an incidental finding at autopsy. There were two patient groups identified: those with disseminated disease (six) and those with localized disease (two). The clinical course of the eight patients is summarized in Table 3 .
Five of the six patients with disseminated disease had fever, generalized lymphadenopathy, respiratory compromise and rising liver transaminases. These patients had a rapidly progressive course and died with multi-organ failure within 3-8 days of the onset of symptoms/signs. In two patients (UPN 993 and 1055) the diagnosis was established by liver biopsy. One of these patients also had abnormal circulating lymphocytes, which, on immunophenotypic analysis by flow cytometry, were positive for CD45, CD19, CD20, CD23, HLA DR and demonstrated kappa light chain restriction. This patient (UPN 1055) was admitted to hospital on day 74 post BMT with fever and rising liver enzymes. Abdominal ultrasound and CT scan showed mild hepatosplenomegaly and lymphadenopathy involving the porta hepatis and splenic hilum. Liver enzymes and bilirubin continued to increase and a liver biopsy on day 76 confirmed PTLD. Treatment comprised discontinuation of cyclosporine and methylprednisolone as well as institution of acyclovir. Donor peripheral blood leukocytes (5 × 10 7 CD3 cells ie 1 × 10 6 CD3 cells/kg) were infused on day 77 according to the report of Papadopoulos et al. 12 She continued to deteriorate and developed multi-organ failure involving liver, kidneys, lungs and heart. She died on day 79 post BMT. The other patient (UPN 993) was being treated for grade IV GVHD (skin and gastrointestinal tract) and pulmonary aspergillosis when she developed fever and increasing liver enzymes on day 139 post BMT. A liver biopsy confirmed PTLD. She deteriorated rapidly with high fever, liver and respiratory failure and died on day 142 post BMT. Autopsy revealed PTLD involving the thyroid, liver, spleen, kidneys, adrenals, large bowel, lymph nodes and bone marrow. Three of the remaining four patients with disseminated disease (UPN 992, 1028 and 1107) had similar clinical courses characterized by sudden onset of fever, respiratory compromise and increasing liver enzymes with progressive deterioration culminating in death from multiorgan failure within 6-8 days of onset of symptoms/signs. Post mortem examination revealed disseminated PTLD. The last patient (UPN 258) had ongoing problems with GVHD, cyclosporine-induced microangiopathic hemolytic anemia, respiratory failure from CMV interstitial pneumonitis which required mechanical ventilation and secondary graft failure. He died on day 107 post BMT and PTLD involving lung and bone marrow was discovered as an incidental finding at post mortem examination. PTLD was considered not to have contributed to his death.
Two patients (UPN 954 and 1006) had localized disease. One (UPN 954) presented on day 282 post first BMT (day 50 post second BMT) for CML with tonsillitis that was refractory to repeated courses of antibiotics. Following a tonsillar biopsy which confirmed PTLD, cyclosporine was discontinued. The lymphoma regressed and he did not develop GVHD. He is alive and free of disease at 3.5 years post first BMT. The other patient (UPN 1006) died of Incidental finding at post mortem examination. PTLD = post transplant lymphoproliferative disorder; UPN = unique patient number; CMV-IP = cytomegalovirus interstitial pneumonitis; GVHD = graftversus-host disease; CsA = cyclosporin A; DLI = donor leukocyte infusion. GVHD and invasive aspergillosis; post mortem examination revealed a peri-pancreatic focus of PTLD that probably did not contribute to her death.
Pathology
Based on morphology and immunophenotype, the cases were classified into diffuse large B cell lymphoma (DLBC lymphoma) and polymorphous B cell hyperplasia (PBCH). [13] [14] [15] The five cases of DLBC lymphoma all showed diffuse proliferation of large cleaved and noncleaved cells (Figure 1) , with clonality being demonstrated by immunophenotyping and/or PCR. The three cases of PBCH all showed a diffuse proliferation characterized by a spectrum of cells consisting of small and large cleaved and non-cleaved lymphocytes, small lymphocytes some with plasmacytoid differentiation, plasma cells and immu- noblasts (Figure 2) . Two of these cases showed evidence of clonality: one by immunophenotyping with kappa light chain restriction and the other by PCR. EBV was present in all eight cases; seven cases tested using LMP immunostaining were positive and all five analyzed by PCR were positive, including the single case not studied by LMP immunostaining. The results are summarized in Table 4 .
Risk factors for the development of PTLD
By univariate analysis, the following factors were significantly associated with the development of PTLD following BMT: treatment of acute GVHD with ATG, Xomazyme or BT 563 (P Ͻ 0.0001); T cell depletion of the allograft (P = 0.0001); TBI-based + ATG conditioning regimen (P = 0.0002); acute GVHD grades 3-4 (P = 0.0009); marrow from an UD (P = 0.01).
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Table 4
Results of pathological investigations By multivariate analysis, three factors remained statistically significant: T cell depletion of the allograft; treatment of acute GVHD with ATG, Xomazyme or BT 563; acute GVHD grades 3-4. These results are shown in Table 5 .
Discussion
PTLD is a recognized complication of BMT; however, it has been difficult to characterize because most transplant centers have only a limited experience with small numbers of patients and the clinical presentation of the disease is diverse. [2] [3] [4] [5] In addition, morphological classification, EBV positivity and clonality do not appear to correlate with each other or with the clinical course. As a result, a systematic approach to diagnosis, prognosis and treatment has not been possible. Recently, an international consensus development meeting on EBV-induced PTLD (Chicago, May 1997) was convened to develop guidelines for diagnosis and treatment. The need for a central registry was also identified. It is hoped that this initiative will lead to a better understanding of PTLD and thus improved treatment.
Most cases of PTLD following BMT occur in patients who have received a T cell-depleted marrow graft or have been treated with in vivo anti-T cell therapy. In our series of eight patients, five received a T cell-depleted BMT and Table 5 Multivariate analysis of risk factors for the development of PTLD all patients received ATG or Xomazyme as part of the conditioning regimen or for treatment of severe GVHD. In fact, five patients received two courses of ATG. In the multivariate analysis, three variables were significantly associated with the development of PTLD following BMT: T cell depletion of the allograft, development of acute GVHD grades 3-4 and the treatment of GVHD with ATG, Xomazyme or BT 563. This experience is in accord with that of other centers. [2] [3] [4] [5] However, it should be noted that, although the majority of cases occur in such high-risk patients, there are reports of PTLD even after autologous BMT. [16] [17] [18] In our eight cases, the pathology was either DLBC lymphoma (five) or PBCH (three). The six patients with disseminated disease were equally grouped between DLBC lymphoma and PBCH. Both of the patients with localized disease had DLBC lymphoma. More recent reports suggest that, because of overlapping characteristics, DLBC lymphoma and PBCH should be grouped into one category of PTLD (polymorphic PTLD) and that immunoblastic lymphoma and multiple myeloma represent another more aggressive category. 5, 15, 19 None of our patients had immunoblastic lymphoma, although five died of very aggressive and widespread PTLD. Thus, based on our results, morphology does not separate these lymphomas by aggressiveness of clinical course or into localized vs disseminated disease. Whether or not clonality correlates with the clinical course is unclear. All of the seven cases assessed for clonality were monoclonal. It has been hypothesized that patients with a polyclonal infiltrate have an earlier stage of disease that has yet to transform to a true malignancy. 13 If this were true, patients with polyclonal disease might be easier to treat than those with monoclonal disease. One of the patients with localized disease that was classified by morphology as DLBC lymphoma and was found to be monoclonal, responded to discontinuation of immunosuppressive therapy as the only form of treatment for the PTLD. Thus, although monoclonality is more often seen in polymorphic PTLD, it does not predict for poor response to treatment in all cases. As in other reports of PTLD following BMT, all of our cases were EBV positive. It is unknown whether EBV-negative PTLD represents the same disease (International Consensus Development Meeting on EBVinduced PTLD, Chicago, May 1997). From this analysis and from others in the literature, 2-5 it does not appear that morphology, clonality or EBV positivity correlate with either clinical course or prognosis.
Overall, the results of treatment have been disappointing. Patients with localized disease have been reported to respond to a number of therapies including discontinuation or decrease of immunosuppression, acyclovir, interferon, anti-B cell monoclonal antibodies and combination chemotherapy. 17, 20, 21 Both of our patients with the localized form of PTLD developed disease more than 200 days post BMT which is considerably later than the patients with disseminated disease. It is presumed that both patients were severely immunosuppressed. UPN 954 was day 50 after a second BMT (day 282 after the first BMT) and had received ATG in the conditioning regimen prior to each BMT. UPN 1006 had refractory GVHD and had been treated with two courses of ATG, thalidomide and PUVA. Thus, from our limited experience, it is not possible to conclude that patients who develop the localized form of the disease do so in the setting of a recovering cellular immunity. Patients with disseminated disease remain the more difficult to treat and are usually given a number of agents simultaneously and, in some cases, donor leukocyte or donor EBV-specific cytotoxic T lymphocyte infusions. 12, 22 Because of the number of agents used, it has been difficult to determine which, if any, treatment strategies are of benefit. Since PTLD is EBV driven, antiviral therapy has been considered. Acyclovir and ganciclovir inhibit viral DNA polymerase and have been shown to decrease oropharyngeal shedding. However, they have no effect on cellular DNA polymerase and do not inhibit in vitro EBV-induced transformation. Most of our patients received acyclovir for HSV prophylaxis early post BMT and ganciclovir for CMV prophylaxis after engraftment. It seems unlikely that the use of these antivirals had any effect on the development or course of the PTLD. Thus, there is no obvious role for acyclovir or ganciclovir as either prophylaxis or treatment of PTLD.
Cellular immunity, as measured by cytotoxic T lymphocyte response against EBV, does not re-develop until approximately 6 months post BMT. 23 Most cases of PTLD develop during this period. In patients who are more immunosuppressed or who have received T cell-depleted marrow grafts, the time to re-development of cellular immunity may be even more prolonged. Restoration of cellular immunity by infusion of donor leukocytes appears to be a promising approach. Papadopoulos et al showed resolution of lymphoma in five patients treated with infusion of 1 × 10 6 CD3 cells/kg. 12 Unfortunately, the patient (UPN 1055) we treated in this way had no response and died a few days later. Although we did not use donor leukocytes to treat the other four patients who had similarly disseminated PTLD, it is unlikely that this strategy would have been of benefit as the disease was very aggressive and death occurred within 3-8 days of the onset of symptoms/ signs. Viral-specific cytotoxic T lymphocytes may avoid the potential complication of GVHD and, therefore, be a better option. Rooney et al 22 reported that EBV-specific cytotoxic T lymphocytes were effective in controlling PTLD in three patients and were used as prophylaxis in another seven. In addition, these EBV-specific cytotoxic T lymphocytes persist for extended periods as demonstrated by gene marking studies. 22, 24 Restoration of cellular immunity for prophylaxis against PTLD in high-risk patients may be a future option. The EBV-specific cytotoxic T lymphocytes could serve as an interim measure until the restoration of cellular immunity, approximately 6 months post BMT.
In this study of eight cases of PTLD following BMT, we have identified two patterns of disease: one is disseminated, rapidly progressive and most often fatal and the other is localized, relatively indolent and may respond to therapy. Morphological classification, EBV positivity and clonality do not appear to correlate with clinical course or prognosis. Ex vivo T cell depletion of the allograft and in vivo anti-T cell therapy for GVHD are major risk factors for the development of this complication. This experience, like that of others, underscores the need to develop guidelines for the diagnosis and prophylaxis/treatment of PTLD.
